Document:

EX-10.24

 [####] Certain information in this document has been omitted from this exhibit because it is both (i) not
material and (ii) would be competitively harmful if publicly disclosed. 
 Exhibit 10.24 

Dated                       
                                         
23 January 2021 
 LOCKBODY THERAPEUTICS LTD 

AND 
 INITIAL
PARTICIPANTS 
 AND 

UNITED MEDICINES BIOPHARMA LIMITED 

INCENTIVISATION DEED 

relating to 
 LOCKBODY
THERAPEUTICS LTD 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	 1.
	 	Definitions	  	 	1	 
	 2.
	 	Interpretation	  	 	7	 
	 3.
	 	Success Payments	  			
	 4.
	 	Disqualified Participants	  	 	10	 
	 5.
	 	New Participants	  	 	10	 
	 6.
	 	Tax	  	 	11	 
	 7.
	 	Further Assurance	  	 	11	 
	 8.
	 	Confidentiality	  	 	11	 
	 9.
	 	Costs and expenses	  	 	11	 
	 10.
	 	Cumulative remedies	  	 	12	 
	 11.
	 	Waiver	  	 	12	 
	 12.
	 	Entire agreement	  	 	12	 
	 13.
	 	Termination	  	 	12	 
	 14.
	 	Amendments	  	 	13	 
	 15.
	 	Set Off	  	 	13	 
	 16.
	 	No partnership	  	 	14	 
	 17.
	 	Assignment and transfer	  	 	14	 
	 18.
	 	Rights of third parties	  	 	14	 
	 19.
	 	Counterparts; No originals	  	 	14	 
	 20.
	 	Notices	  	 	14	 
	 21.
	 	Severance	  	 	15	 
	 22.
	 	Governing law	  	 	15	 
	 23.
	 	Jurisdiction	  	 	15	 
	 SCHEDULE 1 : THE INITIAL PARTICIPANTS
	  			
	 SCHEDULE 2 : DEED OF ADHERENCE
	  	 	17	 

DATE                         
        23 January 2021 
 PARTIES 

 

	(1)	 LOCKBODY THERAPEUTICS LTD (formerly known as Ultrahuman Six Limited), a private company limited by
shares incorporated in England with company number 10650186 with its registered office at C/O Kreston Reeves LLP, Innovation House, Ramsgate Road, Sandwich, Kent, United Kingdom, CT13 9FF (the “Company”); 

 

	(2)	 THE INITIAL PARTICIPANTS whose names and addresses are set out in columns 1 and 2 of Schedule 1
(together the “Initial Participants”); and 

  

	(3)	 UNITED MEDICINES BIOPHARMA LIMITED, a private company limited by shares incorporated in England with
company number 12973576 and with its registered office at The Dorothy Hodgkin Building, Babraham Research Campus, Babraham, Cambridge, United Kingdom, CB22 3FH (“UM”). 

INTRODUCTION 
  

	(A)	 At Completion, UM shall acquire the entire issued share capital of the Company in consideration for the
issuance of new shares in UM pursuant to a contribution agreement entered into between UM, the Company and the selling shareholders of the Company on or about the date of this Deed (the “Contribution Agreement”).

  

	(B)	 The parties have entered into this Deed to incentivise the Participants to reach the Company’s milestones
and/or achieve a Partial Asset Sale and/or Exit (each as defined below). 

 AGREED TERMS 

 

	1.	 DEFINITIONS 

In this Deed, except where a different interpretation is necessary in the context, the words and expressions set out below shall have the
following meanings: 
 “Act” means the Companies Act 2006, as amended and/or superseded from time to time; 

“Acting in Concert” has the meaning given to it in The City Code on Takeovers and Mergers published by the Panel on
Takeovers and Mergers (as amended and/or superseded from time to time); 
 “Active Participants” means those
Participants who are Employees at the relevant time; 
 “Adverse Event” means any milestone set out in the Business
Plan not being achieved within the specified time period and the UM Representative (acting reasonably and following consultation with the Active Participants) determining that the missed milestone should not be waived and/or the specified time
period should not be extended pursuant to the terms of the Portfolio Company Agreement; 
 “Asset Sale” means the
sale or other disposal (in one transaction or a series of related transactions) by the Company and/or any other member of the Group of all or substantially all of the commercially valuable assets of the Group. For these purposes a
“disposal” may include, without limitation, the grant by the Company and/or any other member of the Group of an exclusive licence in respect of all or substantially all of the commercially valuable assets of the Group, provided that such a
licence shall only constitute an “Asset Sale” for the purposes of this Deed if it is an exclusive licence over the whole of the LockBody Platform Technology in all fields of use such that following such grant neither the Company nor any
other member of the Group retains any right to exploit or commercialise: (a) the LockBody Platform Technology in any field of use; or (b) any LockBody Product; 

  
 1 

 “Bad Leaver” means a person who ceases to be an Employee (and does
not otherwise continue to be an Employee) as a consequence of: 
  

	 	(a)	 that person’s dismissal as an Employee for Cause; or 

 

	 	(b)	 such person’s resignation as an Employee in circumstances where the Company would be entitled to dismiss
the Employee for Cause; 

 and, for the avoidance of doubt, if a person ceases to be an Employee (and does not otherwise
continue to be an Employee) as a consequence of a reason other than as set out in (a) or (b), such person shall not be a Bad Leaver but may still be an Intermediate Leaver and/or a Disqualified Participant; 

“Board” means the board of directors of the Company designated by UM and any committee of the board as constituted from time
to time; 
 “Business Day” means a day (which is not a Saturday, Sunday or a public or bank holiday in the following
location) on which banks generally are open in the City of London (England); 
 “Business Plan” means the business plan of
the Company set out in the schedule to the Portfolio Company Agreement; 
 “Cause” means the lawful termination of that
person’s contract of employment or consultancy without notice or payment in lieu of notice as a consequence of that person’s fraud, gross misconduct or material breach of any of his Restrictive Covenants; 

“Completion” has meaning set out in the Contribution Agreement (as defined in the Introduction); 

“Contingent Consideration” means any contingent consideration payable after completion of the Share Sale, Asset Sale or
Partial Asset Sale (as applicable) which is contingent on the occurrence of an event, [####] 
 “Controlling Interest” means
an interest in shares giving to the holder or holders control of the Company within the meaning of section 1124 of the CTA 2010; 

“CTA 2010” means the Corporation Tax Act 2010; 

“Deed of Adherence” means the deed of adherence substantially in the form set out in Schedule 2 (or in such other form as
approved by UM and a Participant Majority); 
 “Designated Asset” means a LockBody Product and/or the LockBody Platform
Technology in respect of a proposed LockBody Platform Technology Licence (as applicable) that is the subject of an irrevocable and unconditional Designation Notice up to a maximum of: 

 

	 	(a)	 two LockBody Products; 

 

	 	(b)	 the LockBody Platform Technology in respect of two LockBody Platform Technology Licences; or

  

	 	(c)	 one LockBody Product and the LockBody Platform Technology in respect of one LockBody Platform Technology
Licence; 

 “Designation Notice” means a letter from and signed by a Participant Majority to the UM
Representative which designates a specific LockBody Product or a proposed LockBody Platform Technology Licence (as applicable) as a Designated Asset, in each case delivered to 

  
 2 

 UM prior to a Partial Asset Sale occurring in respect of such Designated Asset, such
designation becoming irrevocable on the occurrence of: 
  

	 	(a)	 in the case of a LockBody Product, the achievement of a Milestone in respect of such LockBody Product or a
Partial Asset Sale in respect of such LockBody Product; and 

  

	 	(b)	 in the case of the proposed LockBody Platform Technology Licence, the grant of the proposed LockBody Platform
Technology Licence, 

 and for clarity such designation shall be revocable by a Participant Majority before the occurrence
of (a) or (b) above (as applicable); 
 “Disqualification Date” means in the case of a Participant who becomes a
Disqualified Participant: (a) as a result of being a Bad Leaver or an Intermediate Leaver, the Effective Termination Date; and (b) as a result of a material breach of any Restrictive Covenant, the date on which the person first materially
breaches any Restrictive Covenant after having ceased to be an Employee; 
 “Disqualified Participant” means with regards to
any Participant, where he: 
  

	 	(a)	 is a Bad Leaver; 

  

	 	(b)	 is an Intermediate Leaver; or 

 

	 	(c)	 has materially breached any of his Restrictive Covenants (in the case of a Participant who is an Employee, only
after such Participant has ceased to be an Employee); 

 “Effective Termination Date” means the date on
which the Participant’s employment or consultancy terminates; 
 “Employee” means an individual who is employed by, or
who provides direct or indirect consultancy services to, the Company or any Group Company; 
 “Exit” means a Share Sale or
an Asset Sale, in each case excluding any such event undertaken for tax planning purposes or pursuant to a bona fide restructuring; 
 [####]

  
 3 

 [####] 

“Good Leaver” means any Participant who ceases to be an Employee (and does not otherwise continue to be an Employee) by reason
of: (a) death; (b) permanent incapacity; (c) the termination of the Participant’s contract of employment or consultancy by the Company other than for Cause; or (d) UM determining in its sole discretion that such Participant
is a Good Leaver; 
 “Group Companies” means the Company and each and any of the Subsidiaries from time to time, and
“Group Company” shall mean any one of them and “Group” shall be construed accordingly; 
 “Initial
Pro Rata Entitlement” means, with respect to any Participant, such Participant’s pro rata proportion set out against his name in column 4 of the table set out in Schedule 2 hereto; 

“Intermediate Leaver” means any Participant who ceases to be an Employee (and does not otherwise continue to be an Employee)
at any time during the Relevant Period other than where such person is a Good Leaver or a Bad Leaver; 
 “Listing” means the
admission of (or in the case of admission to NASDAQ, the initial public offering of) all or any of the shares in the Company (or the shares of a holding company of the Company, excluding UM and United Medicines Biopharma (Midco) Limited) or
securities representing those shares (including without limitation depositary interests, American depositary receipts, American depositary shares and/or other instruments) to trading on NASDAQ or the Official List of the United Kingdom Listing
Authority or the AIM Market operated by the London Stock Exchange Plc or any other recognised investment exchange (as defined in section 285 of the Financial Services and Markets Act 2000); 

[####] 

  
 4 

 [####] 

“Major Market Countries” means the United States, France, Germany, Italy, Spain and the United Kingdom, and
“Major Market Country” means any of them; 
 “Marketing Approval” means, with respect to a
Designated Asset which is a LockBody Product, in a particular country or jurisdiction, all approvals, licences, permits, certifications, registrations or authorisations necessary for the sale or supply of such Designated Asset in such country or
jurisdiction for human use outside of clinical trials, but excluding pricing or reimbursement approvals; 
 “Milestone”
means Marketing Approval of a Designated Asset which is a LockBody Product in any Major Market Country and, for the avoidance of doubt, the Milestone can only be achieved once by any single Designated Asset which is a LockBody Product, but can be
achieved up to a maximum of two (2) times in the event that two Designated Assets that are LockBody Products receive Marketing Approval; 

“Milestone Payment” means the sum of USD 20,000,000; 

“Month” means the period of time between the same dates in successive calendar months and if there is no such same date, the
last day of the calendar month in question; 
 “New Participant” means any person who becomes a party to this Deed as a
“New Participant” by signing a Deed of Adherence in accordance with clause 5 (New Participants);  
 “Partial Asset
Sale” means the sale or other disposal (in one transaction or a series of related transactions) by the Company and/or any other member of the Group of either Designated Asset. For these purposes a “disposal” may include, without
limitation: 
  

	 	(a)	 the grant by the Company and/or any other member of the Group of an exclusive licence in respect of such a
LockBody Product; or 

  

	 	(b)	 the grant of a LockBody Platform Technology Licence (except where it amounts to an Asset Sale, unless there has
already been a Partial Asset Sale in respect of a Designated Asset, in which case such transaction shall always be treated as a Partial Asset Sale and not as an Asset Sale); 

“Partial Asset Sale Payment” means an amount equal to fifteen per cent (15%) of the Upfront Proceeds in respect of such
Partial Asset Sale, less, in the case of a Designated Asset which is a LockBody Product, an amount equal to the Milestone Payment to the extent that the Milestone has been achieved for such Designated Asset which is a LockBody Product which is the
subject of the Partial Asset Sale, save that: 
  

	 	(a)	 if a Partial Asset Sale occurs following the occurrence of an Adverse Event for such Designated Asset which is
a LockBody Product, the Partial Asset Sale Payment shall be zero if the Upfront Proceeds do not exceed EUR 12,500,000; and 

  

	 	(b)	 the Partial Asset Sale Payment cannot be less than zero (0), i.e. in no event shall the Partial Asset Sale
Payment be a negative amount and/or the Participants be under any obligation to make any repayment or payment to the Company in relation thereto unless required in accordance with clause 4.2(b), 

and it is agreed that an Adverse Event in relation to one Designated Asset shall not affect the Partial Asset Sale Payment for the other
Designated Asset, and, for the avoidance of doubt, in the event that the Upfront Proceeds includes any non-cash consideration which is divisible (including, without limitation, equity securities), such equivalent portion of the Partial Asset Sale
Payment shall be settled (at UM’s discretion) either: 
  

	 	(i)	 by issuing, assigning or otherwise transferring such portion of the divisible non-cash consideration; or

  
 5 

	 	(ii)	 in cash, with the non-cash consideration being deemed to have a cash value equal to the fair market value of
the non-cash consideration or such other value as agreed by the Participants, the Company and UM, 

 and where such Upfront
Proceeds includes any non-cash consideration which is not divisible, such equivalent portion of the Partial Asset Sale Payment shall be settled in cash, with the non-cash consideration being deemed to have a cash value equal to the fair market value
of the non-cash consideration or such other value as agreed by the Participants, the Company and UM; 
 “Participant
Majority” means where there are two Active Participants at least fifty six per cent. (56%) of the aggregate Pro Rata Entitlements held by them for the time being, or where there are more than two Active Participants, at least fifty per
cent. (50%) of the aggregate Pro Rata Entitlements held by them for the time being; 
 “Participants” means each of:
(a) the Initial Participants; and (b) the New Participants, but excluding any Disqualified Participants; 

“Personal Representative” shall mean the legal personal representative(s) of a Participant (being either the executors
of the will or the duly appointed administrator(s) of the estate) who has provided to the Board evidence of their appointment as such; 

“Portfolio Company Agreement” means the portfolio company agreement entered into by the Company, UM and the Initial
Leadership Team (each as defined therein) on or about the date of this Deed (as amended and/or superseded from time to time); 

“Pro Rata Entitlement” means, with respect to any Participant, such Participant’s pro rata proportion of any
Success Payment, which as at the date of this Deed shall be the Initial Pro Rata Entitlement, as amended and/or superseded in accordance with the terms of this Deed; 

[####] 

“Restrictive Covenants” means any obligations of a Participant in respect of confidentiality, intellectual property,
non-solicitation, non-dealing, non-poaching and/or non-competition given in favour of any Group Company or UM in the Portfolio Company Agreement or his/her employment or consultancy agreement with any Group Company, any settlement agreement or other
agreement to which he/she is a party with the Company, any member of the Group and/or UM; 
 “Share Sale” means the sale of
any of the shares (in one transaction or as a series of transactions) which results in the purchaser of the shares and persons Acting in Concert with him together acquiring a Controlling Interest in the Company, except where following completion of
the sale, the shareholders and the proportion of shares held by each of them are the same as the shareholders and their shareholdings in the Company immediately prior to the sale; 

“Shares” means the entire issued share capital of the Company; 

“Subsidiary” means any subsidiary (as defined in section 1159 of the Act) of the Company from time to time; 

[####] 
 “UM
Representative” means the chief executive officer of UM, being at the date of this Deed Saurabh Saha, or such other person(s) as decided by the board of directors of UM and notified to the Company and the Active Participants in writing;

  
 6 

 [####] 
  

	2.	 INTERPRETATION 

 

	2.1	 The clause and paragraph headings and the table of contents used in this Deed are inserted for ease of
reference only and shall not affect construction. 

  

	2.2	 Words and expressions which are defined in the Act shall have the meanings attributed to them therein when used
in this Deed unless otherwise defined or the context otherwise requires. 

  

	2.3	 References to a “clause” or “Schedule” is, unless the context specifically
requires otherwise, to the corresponding clause of or Schedule or appendix to this Deed, and reference to a “paragraph” is, unless the context specifically requires otherwise, a reference to the corresponding paragraph of the
provision in which that reference occurs. 

  

	2.4	 References to persons shall include any natural person, individual, company, bodies corporate, unincorporated
association, firm, corporation, partnership, trust, joint venture or consortium, government, state or agency of a state, and any undertaking, in each case whether or not having separate legal personality and irrespective of the jurisdiction in or
under the laws of which it was incorporated or exists. 

  

	2.5	 Reference to a “party” or “parties” is to a party or parties of this Deed and
shall include any person that has signed a Deed of Adherence. 

  

	2.6	 References to “writing” and “written” include any non-transitory form of
visible reproduction of words. 

  
 7 

	2.7	 References to those of the parties that are individuals include their respective legal Personal Representatives
and any person or entity to whom the rights of this Deed have been assigned under clause 17. 

  

	2.8	 References to the word “include” or “including” (or any similar term) are not
to be construed as implying any limitation and general words introduced by the word “other” (or any similar term) shall not be given a restrictive meaning by reason of the fact that they are preceded or followed by words indicating
a particular class of acts, matters or things. 

  

	2.9	 Except where the context specifically requires otherwise, words importing one gender shall be treated as
importing any gender, words importing individuals shall be treated as importing corporations and vice versa and words importing the singular shall be treated as importing the plural and vice versa. 

 

	2.10	 In this Deed, the term “consultant” includes: 

 

	 	(a)	 a person engaged directly by any Group Company to provide services to any of them; and 

 

	 	(b)	 a person (an “Indirect Consultant”) employed or engaged by a third party (a
“Service Company”) to work in, including but not limited to, the provision of services on behalf of such Service Company to any Group Company, where that Service Company is engaged by any Group Company to provide such
services, 

 and the term “consultancy services” shall include services provided by a consultant
directly and/or as an Indirect Consultant. 
  

	2.11	 Where any sum, amount or liability denominated in one currency as at a particular date is to be translated into
another currency on such date for the purposes of interpreting or giving effect to this Deed, the prevailing foreign currency spot exchange rate published in the Financial Times, London edition, as at that date (or, if not published on such date,
the nearest preceding Business Day) shall apply (or such other exchange rate as the Company, UM and the Participants may agree in writing). 

[####] 

  
 8 

	 	[####]	 

  

  
 9 

	4.	 DISQUALIFIED PARTICIPANTS 

 

	4.1	 In the event that a Participant becomes a Disqualified Participant, the Disqualified Participant shall:

  

	 	(a)	 no longer be entitled to any portion of any Success Payment and his Pro Rata Entitlement shall be zero per
cent. (0%); and 

  

	 	(b)	 cease to be a party to this Deed, 

and, for the avoidance of doubt, in such case the Pro Rata Entitlement of the remaining Participants shall remain the same. 

 

	4.2	 A Disqualified Participant shall: 

 

	 	(a)	 subject to clause 4.2(b), be under no obligation to repay to the Company, UM, any other Participant or any
other third party any Success Payments received prior to the Disqualification Date; 

  

	 	(b)	 repay to the Company forthwith any Success Payments received after the Disqualification Date (for the avoidance
of doubt, no Participant shall be entitled to any amount of any Success Payment repaid to the Company or UM); and 

  

	 	(c)	 no longer be entitled to any portion of any Success Payment, regardless of whether any Success Payment was
payable (but not yet paid) as at the Disqualification Date. 

  

	4.3	 A Disqualified Participant shall have no claim against the Company, any Group Company and/or UM in respect of
his termination of his contract of employment or consultancy in relation to any provision of this Deed which has the effect of requiring the Disqualified Participant to lose their Pro Rata Entitlement of any Success Payment. 

 

	5.	 NEW PARTICIPANTS 

 

	5.1	 Following consultation with the Active Participants, the Board shall have absolute discretion to allocate the
Unallocated Pro Rata Entitlement to any Participant or New Participant and admit any such New Participant to this Deed by such person signing a Deed of Adherence which shall set out such New Participant’s Pro Rata Entitlement. In such case the
Pro Rata Entitlements of the existing Participants shall remain unchanged. 

  

	5.2	 In addition to the right to admit New Participants in clause 5.1, the Board may admit New Participants where
there is insufficient Unallocated Pro Rata Entitlement (provided it has the consent of the Participants (save that no Participant shall unreasonably withhold, delay and/or condition their consent if Participants amounting to a Participant Majority
have provided their consent)) by such person signing a Deed of Adherence which shall set out such New Participant’s Pro Rata Entitlement. In such case the Pro Rata Entitlements of the existing Participants shall decrease by such amount pro rata
to their respective Pro Rata Entitlement so as to allocate the required Pro Rata Entitlement to the New Participant (unless the Participants (with the consent of the Board, which shall not be unreasonably withheld or delayed) unanimously determine
otherwise. 

  

	5.3	 A New Participant who has entered into a Deed of Adherence pursuant to this Deed shall have the benefit of and
be subject to the burden of all the provisions to this Deed as if he were a Participant, and this Deed shall be interpreted accordingly. Nothing in this clause shall be construed as requiring any New Participant to perform again any obligation or
discharge again any liability already performed or discharged or entitle any New Participant to receive again any benefit already enjoyed by the Participants prior to the New Participant becoming a party to this Deed; and nothing herein shall be
construed or interpreted to result in any Participant being obliged to make any compensation payments to the New Participant with respect to any Success Payment that has been paid to a Participant (including a Disqualified Participant) or has become
payable as a result of the achievement of a Milestone or the occurrence of a Partial Asset Sale or Exit prior to the date of the relevant Deed of Adherence. 

  
 10 

	6.	 TAX 

To the extent applicable, the Company shall be entitled to deduct: (a) any income tax due under PAYE and/or any employee national
insurance contributions or any equivalent tax in the relevant jurisdiction; and (b) any other deduction or withholding required by any law or regulation applicable to any Participant (and all and any other deductions required by law) with
respect to any Success Payment paid to such Participant pursuant to this Deed. 
  

	7.	 FURTHER ASSURANCE 

The parties shall at their own cost use all reasonable endeavours from time to time, on being required to do so by any other party, to do or
procure the doing of all such acts and/or execute or procure the execution of all such documents in a form reasonably satisfactory to the other party for giving full effect to this Deed and securing to the other parties the full benefit of the
rights, powers, privileges and remedies conferred upon any party in this Deed. 
  

	8.	 CONFIDENTIALITY 

 

	8.1	 The parties shall (and shall procure, where relevant, that each other member of its group and their respective
officers, employees, agents and advisers shall) preserve the confidentiality of the existence, the terms of this Deed and any information with respect to a Partial Asset Sale or Exit provided to the Participants in accordance clause 3.4, and,
subject to clause 8.2, not directly or indirectly reveal or disclose such information. 

  

	8.2	 Notwithstanding any other provision in this Deed, the parties may disclose the existence and the terms and
conditions of this Deed if and to the extent: 

  

	 	(a)	 required by applicable law or for the purpose of any judicial or arbitral proceedings; 

 

	 	(b)	 required by any securities exchange on which such party’s securities are listed or traded;

  

	 	(c)	 required by any regulatory or governmental or other authority with relevant powers to which such party is
subject or submits (whether or not the requirement has the force of law); 

  

	 	(d)	 required by its professional advisers (including auditors), officers, employees, consultants, sub-contractors
or agents to provide their services (and subject always to similar duties of confidentiality) and any member of its group and their respective officers, employees, agents and advisers; 

 

	 	(e)	 the Company has given its prior written consent to the disclosure; 

 

	 	(f)	 it is necessary to obtain any relevant tax clearances from or otherwise to disclose to comply with any
legislation, regulations, concessions, guidance or practice of any appropriate tax authority; or 

  

	 	(g)	 such information becomes publicly available (other than through a breach of this clause 8
(Confidentiality)). 

  

	9.	 COSTS AND EXPENSES 

The parties shall bear their own costs and disbursements incurred in the negotiations leading up to and in the preparation of this Deed and of
matters incidental to this Deed. 

  
 11 

	10.	 CUMULATIVE REMEDIES 

The rights, powers, privileges and remedies conferred upon the parties in this Deed are cumulative and are not exclusive of any other rights,
powers, privileges or remedies provided by law. 
  

	11.	 WAIVER 

The express or implied waiver by any party to this Deed of any of its rights or remedies arising under this Deed or by law shall not constitute
a continuing waiver of the right or remedy waived or a waiver of any other right or remedy. 
  

	12.	 ENTIRE AGREEMENT 

 

	12.1	 This Deed and the documents referred to or incorporated in it constitute the entire agreement between the
parties relating to the subject matter of this Deed and supersede and extinguish any prior drafts, agreements, undertakings, representations, warranties and arrangements of any nature whatsoever, whether or not in writing, between the parties in
relation to the subject matter of this Deed. 

  

	12.2	 Each of the parties acknowledges and agrees that it has not entered into this Deed in reliance on any statement
or representation of any person (whether a party to this Deed or not) other than as expressly incorporated in this Deed and the documents referred to or incorporated in this Deed. 

 

	12.3	 Without limiting the generality of the foregoing, each of the parties irrevocably and unconditionally waives
any right or remedy it may have to claim damages and/or to rescind this Deed by reason of any misrepresentation (other than a fraudulent misrepresentation) having been made to it by any person (whether party to this Deed or not) and upon which it
has relied in entering into this Deed (other than as expressly incorporated in this Deed and the documents referred to or incorporated in this Deed). 

  

	12.4	 Each of the parties acknowledges and agrees that damages alone may not be an adequate remedy for the breach of
any of the undertakings or obligations as set out in this Deed. Accordingly, without prejudice to any other rights and remedies the parties may have, the parties shall be entitled to seek the remedies of injunction, specific performance or other
equitable relief for any threatened or actual breach of the terms of this Deed. 

  

	12.5	 Nothing contained in this Deed or in any other document referred to or incorporated in it shall be read or
construed as excluding any liability or remedy as a result of fraud. 

  

	13.	 EFFECTIVENESS; TERMINATION 

 

	13.1	 The effectiveness of all rights and obligations under or in connection with this Deed shall be subject to the
condition precedent of the occurrence of Completion and all rights and obligations shall apply as from the date that such condition precedent is fulfilled; provided that if Completion has not occurred by the Longstop Date, this Deed shall
automatically terminate with immediate effect. 

  

	13.2	 Subject to clause 13.3, this Deed shall terminate and be of no further force or effect upon the earlier of:

  

	 	[####]	 

  
 12 

	 	[####]	 

  

	13.3	 On termination of this Deed, clause 8 (Confidentiality) shall survive and continue in full force and
effect but all other rights and obligations of the parties shall cease immediately. Termination shall not affect the parties’ accrued rights and obligations as at such termination, in particular as set out in clause 13.2 above.

  

	13.4	 For the avoidance of doubt, the occurrence of an Adverse Event shall not constitute grounds for any party to
terminate this Deed for cause or otherwise. 

  

	14.	 AMENDMENTS 

  

	14.1	 Subject to clauses 3.6 and 14.2, all and any of the provisions of this Deed may only be deleted, varied,
supplemented, restated or otherwise changed in any way at any time with the prior written consent of the Company, UM and Participants holding at least a majority of the aggregate Pro Rata Entitlements, in which event such change shall be binding
against all the parties hereto provided that if such change would impose any new obligations on any Participant(s) that is not imposed on all other Participants or increase any existing obligation of any Participant(s) that is not increased for all
other Participants, the consent of the affected Participant(s) to such amendment shall be specifically required. 

  

	14.2	 The Pro Rata Entitlements of the Participants may only be amended with the consent in writing of all of the
Participants (and the Board, which shall not be unreasonably withheld or delayed) or as otherwise provided for in accordance with clauses 3.6, 4 (Disqualified Participants) or 5.2. 

 

	15.	 SET OFF 

The Company may at any time set off any actual liability of any Participant to the Company (as applicable) against any actual liability of the
Company to the Participant, whether either liability is present or future, liquidated or unliquidated, and whether or not either liability arises under this Deed. If the liabilities to be set off are expressed in different currencies, the Company
may convert either liability at a market rate of exchange for the purpose of set-off. Any exercise by the Company of its rights under this clause shall not limit or affect any other rights or remedies available to it under this Deed or otherwise.

  
 13 

	16.	 NO PARTNERSHIP 

Nothing in this Deed is intended to or shall be construed as establishing or implying any partnership of any kind between the parties. 

 

	17.	 ASSIGNMENT AND TRANSFER 

 

	17.1	 Subject to clauses 17.3 and 17.4, this Deed is personal to the parties and no party shall:

  

	 	(a)	 assign any of its rights under this Deed; 

 

	 	(b)	 transfer any of its obligations under this Deed; 

 

	 	(c)	 sub-contract or delegate any of its obligations under this Deed; or 

 

	 	(d)	 charge or deal in any other manner with this Deed or any of its rights or obligations. 

 

	17.2	 Subject to clauses 17.3 and 17.4, any purported assignment, transfer, sub-contracting, delegation, charging or
dealing in contravention of clause 17.1 shall be ineffective. 

  

	17.3	 A Participant’s rights under this Deed shall be assigned automatically to their Personal Representative on
death and the Personal Representative shall notify UM of such assignment as soon as reasonably practical. 

  

	17.4	 A Participant or their Personal Representative can assign any rights under this Deed with consent in writing
from UM and on such terms and as determined by UM in its absolute discretion (save that in the case of a Personal Representative, UM’s consent shall not be unreasonably withheld, conditioned or delayed provided that the obligations and/or
liability of the Company and/or UM is not increased as a result of the assignment). 

  

	18.	 RIGHTS OF THIRD PARTIES 

This Deed does not confer any rights on any person or party (other than the parties) pursuant to the Contracts (Rights of Third Parties) Act
1999. 
  

	19.	 COUNTERPARTS; NO ORIGINALS 

This Deed may be executed in any number of counterparts, each of which shall constitute an original, and all the counterparts shall together
constitute one and the same agreement. The exchange of a fully executed version of this Deed (in counterparts or otherwise) by electronic transmission (including pdf or other digital format including any electronic signature complying with the
Electronic Signatures in Global and National Commerce Act 2000, e.g., www.docusign.com) and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes and shall be sufficient to
bind the parties to the terms and conditions of this Deed. No exchange of original signatures is necessary. 
  

	20.	 NOTICES 

  

	20.1	 To be valid, any communication and/or information to be given in connection with this Deed must be in writing
in English and either be delivered by hand or sent by first class post, email or other electronic form: 

  

	 	(a)	 to any body corporate which is a party at its registered office; or 

 

	 	(b)	 to any Participant at the address of that Participant shown in Schedule 1, 

  
 14 

 or in each such case such other address as the recipient may notify to the other parties for
such purpose in accordance with this clause 20 (Notices). 
  

	20.2	 A communication sent according to clause 20.1 shall be deemed to have been received: 

 

	 	(a)	 if delivered by hand, at the time of delivery; 

 

	 	(b)	 if sent by pre-paid first class post, on the second day after posting; or 

 

	 	(c)	 if sent by email or other electronic form, at the time of completion of transmission by the sender;

 except that if a communication is received between 17:30 on a Business Day and 09:30 on the next Business Day, it shall
be deemed to have been received at 09:30 on the second of such Business Days. 
  

	21.	 SEVERANCE 

  

	21.1	 If any provision of this Deed is held to be invalid or unenforceable by any judicial or other competent
authority, all other provisions of this Deed will remain in full force and effect and will not in any way be impaired. 

  

	21.2	 If any provision of this Deed is held to be invalid or unenforceable but would be valid or enforceable if some
part of the provision were deleted or modified, the provision in question will apply with the minimum modifications necessary to make it valid and enforceable. 

 

	22.	 GOVERNING LAW 

This Deed (and any dispute or claim relating to it or its subject matter (including non-contractual claims)) is governed by and is to be
construed in accordance with English law. 
  

	23.	 JURISDICTION 

The parties irrevocably agree that the courts of England and Wales shall have exclusive jurisdiction to settle any claim, dispute or issue
(including non-contractual claims) which may arise out of or in connection with this Deed. 
 [Intentionally left blank, the schedules and
signature pages follow.] 

  
 15 

 [####] 
  

  
 16 

 SCHEDULE 2 : [####] 

 

  
 17 

 This Deed has been executed and delivered as a deed on the date shown on the first page. 

 

					
	Executed and delivered as a Deed by	  	)	  	[####]
	UNITED MEDICINES BIOPHARMA	  	)	  	
	LIMITED	  	)	  	
		  		  	
	acting by:[####]	  		  	
	Position:	  		  	
			
	In the presence of:	  		  	
			
	Signature of Witness	  		  	
			
	Name of Witness	  		  	
			
	Address of Witness	  		  	
			
	Occupation of Witness	  		  	
			
	Executed and delivered as a Deed by	  	)	  	
	LOCKBODY THERAPEUTICS LTD	  	)	  	
		  	)	  	  

	acting by:	  		  	Signature
	Position:	  		  	
			
	In the presence of:	  		  	
			
	Signature of Witness	  		  	  

			
	Name of Witness	  		  	  

			
	Address of Witness	  		  	  

			
	Occupation of Witness	  		  	  

			
	Executed and delivered as a DEED by	  	)	  	
	[####]	  	)	  	
		  	)	  	  

		  		  	Signature
			
	In the presence of:	  		  	
			
	Signature of Witness	  		  	  

			
	Name of Witness	  		  	  

			
	Address of Witness	  		  	  

			
	Occupation of Witness	  		  	  

  
 18 

 This Deed has been executed and delivered as a deed on the date shown on the first page. 

 

					
	Executed and delivered as a Deed by	  	)	  	
	[####]	  	)	  	
	[####]	  	)	  	  

		  		  	Signature
	acting by:	  		  	
	Position:	  		  	
			
	In the presence of:	  		  	
			
	Signature of Witness	  		  	  

			
	Name of Witness	  		  	  

			
	Address of Witness	  		  	  

			
	Occupation of Witness	  		  	  

			
	Executed and delivered as a Deed by	  	)	  	
	LOCKBODY THERAPEUTICS LTD	  	)	  	
		  	)	  	
	acting by: [####]	  		  	[####]
	Position: [####]	  		  	
			
	In the presence of:	  		  	
			
	Signature of Witness	  		  	
			
	Name of Witness	  		  	
			
	Address of Witness	  		  	
			
	Occupation of Witness	  		  	
			
	Executed and delivered as a DEED by	  	)	  	
	[####]	  	)	  	
		  	)	  	  

		  		  	Signature
			
	In the presence of:	  		  	
			
	Signature of Witness	  		  	  

			
	Name of Witness	  		  	  

			
	Address of Witness	  		  	  

			
	Occupation of Witness	  		  	  

  
 19 

 This Deed has been executed and delivered as a deed on the date shown on the first page. 

 

					
	Executed and delivered as a Deed by	  	)	  	
	UNITED MEDICINES BIOPHARMA	  	)	  	
	LIMITED	  	)	  	  

		  		  	Signature
	acting by:	  		  	
	Position:	  		  	
			
	In the presence of:	  		  	
			
	Signature of Witness	  		  	  

			
	Name of Witness	  		  	  

			
	Address of Witness	  		  	  

			
	Occupation of Witness	  		  	  

			
	Executed and delivered as a Deed by	  	)	  	
	LOCKBODY THERAPEUTICS LTD	  	)	  	
		  	)	  	  

	acting by:	  		  	Signature
	Position:	  		  	
			
	In the presence of:	  		  	
			
	Signature of Witness	  		  	  

			
	Name of Witness	  		  	  

			
	Address of Witness	  		  	  

			
	Occupation of Witness	  		  	  

			
	Executed and delivered as a DEED by	  	)	  	[####]
	[####]	  	)	  	
		  	)	  	
		  		  	
			
	In the presence of:	  		  	
			
	Signature of Witness	  		  	
			
	Name of Witness	  		  	
			
	Address of Witness	  		  	
			
	Occupation of Witness	  		  	

  
 20 

					
	Executed and delivered as a DEED by	  	)	  	
	[####]	  	)	  	
		  	)	  	[####]
		  		  	
			
	In the presence of:	  		  	
			
	Signature of Witness	  		  	
			
	Name of Witness	  		  	
			
	Address of Witness	  		  	
			
	Occupation of Witness	  		  	

  
 21EX-10.25

 [####] Certain information in this document has been omitted from this exhibit because it is both (i) not
material and (ii) would be competitively harmful if publicly disclosed. 
 Exhibit 10.25 

Private & Confidential 
  

 
  

									
		  	Dated	  		  	23 January 2021	  	

 MORPHOGEN-IX LIMITED 

AND 
 INITIAL
PARTICIPANTS 
 AND 

UNITED MEDICINES BIOPHARMA LIMITED 

INCENTIVISATION DEED 

relating to 
 MORPHOGEN-IX LIMITED 

 Private & Confidential 

 
  

TABLE OF CONTENTS 
  

							
	 	  	 	  	Page	 
			
	1.	  	 Definitions
	  	 	1	 
			
	2.	  	 Interpretation
	  	 	5	 
			
	3.	  	 Success Payments
	  	 	6	 
			
	4.	  	 Disqualified Participants
	  	 	7	 
			
	5.	  	 New Participants
	  	 	8	 
			
	6.	  	 Tax
	  	 	8	 
			
	7.	  	 Further Assurance
	  	 	8	 
			
	8.	  	 Confidentiality
	  	 	9	 
			
	9.	  	 Costs and expenses
	  	 	9	 
			
	10.	  	 Cumulative remedies
	  	 	9	 
			
	11.	  	 Waiver
	  	 	9	 
			
	12.	  	 Entire agreement
	  	 	9	 
			
	13.	  	 Effectiveness; Termination
	  	 	10	 
			
	14.	  	 Amendments
	  	 	11	 
			
	15.	  	 Set Off
	  	 	11	 
			
	16.	  	 No partnership
	  	 	11	 
			
	17.	  	 Assignment and transfer
	  	 	11	 
			
	18.	  	 Rights of third parties
	  	 	12	 
			
	19.	  	 Counterparts; No originals
	  	 	12	 
			
	20.	  	 Notices
	  	 	12	 
			
	21.	  	 Severance
	  	 	12	 
			
	22.	  	 Governing law
	  	 	13	 
			
	23.	  	 Jurisdiction
	  	 	13	 
		
	 SCHEDULE 1 : THE INITIAL PARTICIPANTS
	  	 	14	 
		
	 SCHEDULE 2 : DEED OF ADHERENCE
	  	 	15	 

DATE                        
23 January 2021 
 PARTIES 
  

	(1)	 MORPHOGEN-IX LIMITED, a private company limited by shares
incorporated in England with company number 09686738 with its registered office at C/O The Cambridge Partnership Ltd, The Dorothy Hodgkin Building, Babraham Research Campus, Babraham, Cambridge, United Kingdom, CB22 3FH (the
“Company”); 

  

	(2)	 THE INITIAL PARTICIPANTS whose names and addresses are set out in columns 1 and 2 of Schedule 1
(together the “Initial Participants”); and 

  

	(3)	 UNITED MEDICINES BIOPHARMA LIMITED, a private company limited by shares incorporated in England with
company number 12973576 and with its registered office at The Dorothy Hodgkin Building, Babraham Research Campus, Babraham, Cambridge, United Kingdom, CB22 3FH (“UM”). 

INTRODUCTION 
  

	(A)	 At Completion, UM shall acquire the entire issued share capital of the Company in consideration for the
issuance of new shares in UM pursuant to a contribution agreement entered into on or about the date of this Deed by UM, the Company and the selling shareholders of the Company (the “Contribution Agreement”). 

 

	(B)	 The parties have entered into this Deed to incentivise the Participants to reach the Company’s milestones
and/or achieve an Exit (as defined below). 

 AGREED TERMS 

 

	1.	 DEFINITIONS 

In this Deed, except where different interpretation is necessary in the context, the words and expressions set out below shall have the
following meanings: 
 “Act” means the Companies Act 2006, as amended and/or superseded from time to time; 

“Acting in Concert ” has the meaning given to it in The City Code on Takeovers and Mergers published by the Panel on
Takeovers and Mergers (as amended and/or superseded from time to time); 
 “Active Participants” means those Participants
who are Employees at the relevant time; 
 “Adverse Event” means any milestone set out in the Business Plan not being
achieved within the specified time period and the UM Representative (acting reasonably and following consultation with the Active Participants) determining that the missed milestone should not be waived and/or the specified time period should not be
extended pursuant to the terms of the Portfolio Company Agreement; 
 “Asset Sale” means the sale or other disposal (in one
transaction or a series of related transactions) by the Company and/or any other member of the Group of the Lead Asset. For these purposes a “disposal” may include, without limitation, the grant by the Company and/or any other member of
the Group of an exclusive licence in respect of the Lead Asset; 
 “Bad Leaver” means a person who ceases to be an Employee
(and does not otherwise continue to be an Employee) as a consequence of: 
  

	 	(a)	 that person’s dismissal as an Employee for Cause; or 

  
 1 

	 	(b)	 such person’s resignation as an Employee in circumstances where the Company would be entitled to dismiss
the Employee for Cause; 

 and, for the avoidance of doubt, if a person ceases to be an Employee (and does not otherwise
continue to be an Employee) as a consequence of a reason other than as set out in (a) or (b), such person shall not be a Bad Leaver but may still be an Intermediate Leaver and/or a Disqualified Participant; 

“Board” means the board of directors of the Company designated by UM and any committee of the board as constituted from time
to time; 
 “Business Day” means a day (which is not a Saturday, Sunday or a public or bank holiday in the following
location) on which banks generally are open in the City of London (England); 
 “Business Plan” means the business plan of
the Company set out in the schedule to the Portfolio Company Agreement; 
 “Cause” means the lawful termination of that
person’s contract of employment or consultancy without notice or payment in lieu of notice as a consequence of that person’s fraud, gross misconduct or material breach of any of his Restrictive Covenants; 

“Completion” has meaning set out in the Contribution Agreement (as defined in the Introduction); 

“Contingent Consideration” means any contingent consideration payable after completion of the Share Sale or Asset Sale (as
applicable) which is contingent on the occurrence of an event, [####]. 
 “Controlling Interest” means an interest in
shares giving to the holder or holders control of the Company within the meaning of section 1124 of the CTA 2010; 

“CTA 2010” means the Corporation Tax Act 2010; 

“Deed of Adherence ” means the deed of adherence substantially in the form set out in Schedule 2 (or in such
other form as approved by UM and a Participant Majority); 
 “Disqualification Date” means in the case of a Participant who
becomes a Disqualified Participant: (a) as a result of being a Bad Leaver or an Intermediate Leaver, the Effective Termination Date; and (b) as a result of a material breach of any Restrictive Covenant, the date on which the person first
materially breaches any Restrictive Covenant after having ceased to be an Employee; 
 “Disqualified Participant” means
with regards to any Participant, where he: 
  

	 	(a)	 is a Bad Leaver; 

  

	 	(b)	 is an Intermediate Leaver; or 

 

	 	(c)	 has materially breached any of his Restrictive Covenants (in the case of a Participant who is an Employee, only
after such Participant has ceased to be an Employee);  

 “Effective Termination Date” means the
date on which the Participant’s employment or consultancy terminates; 
 “Employee” means an individual who is
employed by, or who provides direct or indirect consultancy services to, the Company or any Group Company; 

  
 2 

 “Exit” means a Share Sale or an Asset Sale, in each case excluding any such
event undertaken for tax planning purposes or pursuant to a bona fide restructuring;  
 [####] 

 

	 	[####]	 

  

	 	[####]	 

[####] 
  

	 	[####]	 

  

	 	[####]	 

[####] 
 “Good
Leaver” means any Participant who ceases to be an Employee (and does not otherwise continue to be an Employee) by reason of: (a) death; (b) permanent incapacity; (c) the termination of the Participant’s contract
of employment or consultancy by the Company other than for Cause; or (d) UM determining in its sole discretion that such Participant is a Good Leaver; 

“Group Companies” means the Company and each and any of the Subsidiaries from time to time, and “Group
Company” shall mean any one of them and “Group” shall be construed accordingly; 
 “Initial Pro Rata
Entitlement” means, with respect to any Participant, such Participant’s pro rata proportion set out against his name in column 4 of the table set out in Schedule 2 hereto; 

“Intermediate Leaver” means any Participant who ceases to be an Employee (and does not otherwise continue to be an
Employee) at any time during the Relevant Period other than where such person is a Good Leaver or a Bad Leaver; 
 “Lead
Asset” means MGX292, and other variants of BMP9 or BMP10 as well as, any prodrug, fragment, subunit, variant, mutant, oligomer, multimer, isoform, derivative, conjugate or fusion molecule thereof that is covered by one or more of the
patents or patent applications held by a Group Company, or as otherwise agreed in writing by UM and all of the Participants from time to time; 

“Listing” means the admission of (or in the case of admission to NASDAQ, the initial public offering of) all or any of the
shares in the Company (or the shares of a holding company of the Company, excluding UM and United Medicines Biopharma (Midco) Limited) or securities representing those shares (including without limitation depositary interests, American depositary
receipts, American depositary shares and/or other instruments) to trading on NASDAQ or the Official List of the United Kingdom Listing Authority or the AIM Market operated by the London Stock Exchange Plc or any other recognised investment exchange
(as defined in section 285 of the Financial Services and Markets Act 2000); 

  
 3 

 [####] 

“Major Market Countries” means the United States, France, Germany, Italy, Spain and the United Kingdom, and “Major
Market Country” means any of them; 
 “Marketing Approval” means, with respect to the Lead Asset in a particular
country or jurisdiction, all approvals, licences, permits, certifications, registrations or authorisations necessary for the sale or supply of the Lead Asset in such country or jurisdiction for human use outside of clinical trials, but excluding
pricing or reimbursement approvals; 
 “Milestone” means Marketing Approval of the Lead Asset in any Major Market Country
and, for the avoidance of doubt, the Milestone can only be achieved once; 
 “Milestone Payment” means the sum of
$20,000,000 (USD twenty million); 
 “Month” means the period of time between the same dates in successive calendar months
and if there is no such same date, the last day of the calendar month in question; 
 “New Participant” means any person
who becomes a party to this Deed as a “New Participant” by signing a Deed of Adherence in accordance with clause 5 (New Participants); 

“Participant Majority” means Active Participants who together hold at least fifty per cent. (50%) of the aggregate Pro
Rata Entitlements held by the Active Participants from time to time; 
 “Participants” means each of:
(a) the Initial Participants; and (b) the New Participants, but excluding any Disqualified Participants; 

“Personal Representative ” shall mean the legal personal representative(s) of a Participant (being either the
executors of the will or the duly appointed administrator(s) of the estate) who has provided to the Board evidence of their appointment as such; 

“Portfolio Company Agreement” means the portfolio company agreement entered into by the Company, UM and the Initial
Leadership Team (each as defined therein) on or about the date of this Deed (as amended and/or superseded from time to time); 

“Pro Rata Entitlement” means, with respect to any Participant, such Participant’s pro rata proportion of any Success
Payment, which as at the date of this Deed shall be the Initial Pro Rata Entitlement, as amended and/or superseded in accordance with the terms of this Deed; 

[####] 
 “Restrictive
Covenants” means any obligations of a Participant in respect of confidentiality, intellectual property, non-solicitation, non-dealing, non-poaching and/or non-competition given in favour of any Group Company or UM in the Portfolio Company Agreement or his/her employment or consultancy agreement with any Group
Company, any settlement agreement or other agreement to which he/she is a party with the Company, any member of the Group and/or UM; 

  
 4 

 “Share Sale” means the sale of any of the shares (in one transaction
or as a series of transactions) which results in the purchaser of the shares and persons Acting in Concert with him together acquiring a Controlling Interest in the Company, except where following completion of the sale, the shareholders and the
proportion of shares held by each of them are the same as the shareholders and their shareholdings in the Company immediately prior to the sale;  

“Shares” means the entire issued share capital of the Company; 

“Subsidiary” means any subsidiary (as defined in section 1159 of the Act) of the Company from time to time; 

[####] 
 “UM
Representative” means the chief executive officer of UM, being at the date of this Deed Saurabh Saha, or such other person(s) as decided by the board of directors of UM and notified to the Company and the Active Participants in writing;

 “Unallocated Pro Rata Entitlement” means 100% less the aggregate of the Pro Rata Entitlements that have been and
remain allocated to Participants. For the avoidance of doubt, no Participant shall be entitled to any portion of a Success Payment that relates to the Unallocated Pro Rata Entitlement; and 

[####] 
  

	 	[####]	 

  

	 	[####]	 

[####] 
  

	2.	 INTERPRETATION 

 

	2.1	 The clause and paragraph headings and the table of contents used in this Deed are inserted for ease of
reference only and shall not affect construction. 

  

	2.2	 Words and expressions which are defined in the Act shall have the meanings attributed to them therein when used
in this Deed unless otherwise defined or the context otherwise requires. 

  

	2.3	 References to a “clause” or “Schedule” is, unless the context specifically
requires otherwise, to the corresponding clause of or Schedule or appendix to this Deed, and reference to a “paragraph” is, unless the context specifically requires otherwise, a reference to the corresponding paragraph of the
provision in which that reference occurs. 

  
 5 

	2.4	 References to persons shall include any natural person, individual, company, bodies corporate, unincorporated
association, firm, corporation, partnership, trust, joint venture or consortium, government, state or agency of a state, and any undertaking, in each case whether or not having separate legal personality and irrespective of the jurisdiction in or
under the laws of which it was incorporated or exists. 

  

	2.5	 Reference to a “party” or “parties” is to a party or parties of this Deed and
shall include any person that has signed a Deed of Adherence. 

  

	2.6	 References to “writing” and “written” include any non-transitory form of visible reproduction of words. 

  

	2.7	 References to those of the parties that are individuals include their respective legal Personal Representatives
and any person or entity to whom the rights of this Deed have been assigned under clause 17. 

  

	2.8	 References to the word “include” or “including” (or any similar term) are not
to be construed as implying any limitation and general words introduced by the word “other” (or any similar term) shall not be given a restrictive meaning by reason of the fact that they are preceded or followed by words indicating
a particular class of acts, matters or things. 

  

	2.9	 Except where the context specifically requires otherwise, words importing one gender shall be treated as
importing any gender, words importing individuals shall be treated as importing corporations and vice versa and words importing the singular shall be treated as importing the plural and vice versa. 

 

	2.10	 In this Deed, the term “consultant” includes: 

 

	 	(a)	 a person engaged directly by any Group Company to provide services to any of them; and

  

	 	(b)	 a person (an “Indirect Consultant”) employed or engaged by a third party (a “Service
Company”) to work in, including but not limited to, the provision of services on behalf of such Service Company to any Group Company, where that Service Company is engaged by any Group Company to provide such services,

 and the term “consultancy services ” shall include services provided by a consultant directly
and/or as an Indirect Consultant. 
  

	2.11	 Where any sum, amount or liability denominated in one currency as at a particular date is to be translated into
another currency on such date for the purposes of interpreting or giving effect to this Deed, the prevailing foreign currency spot exchange rate published in the Financial Times, London edition, as at that date (or, if not published on such date,
the nearest preceding Business Day) shall apply (or such other exchange rate as the Company, UM and the Participants may agree in writing). 

  

	[####]	 

  

	[####]	 

  

	[####]	 

  

	 	[####]	 

  

	 	[####]	 

  
 6 

 [####] 
  

	[####]	 

  

	 	[####]	 

  

	 	[####]	 

  

	 	[####]	 

  

	 	[####]	 

  

	[####]	 

  

	[####]	 

  

	[####]	 

  

	4.	 DISQUALIFIED PARTICIPANTS 

 

	4.1	 In the event that a Participant becomes a Disqualified Participant, the Disqualified Participant shall:

  

	 	(a)	 no longer be entitled to any portion of any Success Payment and his Pro Rata Entitlement shall be zero per
cent. (0%); and 

  

	 	(b)	 cease to be a party to this Deed, 

and, for the avoidance of doubt, in such case the Pro Rata Entitlement of the remaining Participants shall remain the same. 

 

	4.2	 A Disqualified Participant shall: 

  
 7 

	 	(a)	 subject to clause 4.2(b), be under no obligation to repay to the Company, UM, any other Participant or any
other third party any Success Payments received prior to the Disqualification Date; 

  

	 	(b)	 repay to the Company forthwith any Success Payments received after the Disqualification Date (for the avoidance
of doubt, no Participant shall be entitled to any amount of any Success Payment repaid to the Company or UM); and 

  

	 	(c)	 no longer be entitled to any portion of any Success Payment, regardless of whether any Success Payment was
payable (but not yet paid) as at the Disqualification Date. 

  

	4.3	 A Disqualified Participant shall have no claim against the Company, any Group Company and/or UM in respect of
his termination of his contract of employment or consultancy in relation to any provision of this Deed which has the effect of requiring the Disqualified Participant to lose their Pro Rata Entitlement of any Success Payment. 

 

	5.	 NEW PARTICIPANTS 

 

	5.1	 Following consultation with the Active Participants, the Board shall have absolute discretion to allocate the
Unallocated Pro Rata Entitlement to any Participant or New Participant and admit any such New Participant to this Deed by such person signing a Deed of Adherence which shall set out such New Participant’s Pro Rata Entitlement. In such case the
Pro Rata Entitlements of the existing Participants shall remain unchanged. 

  

	5.2	 In addition to the right to admit New Participants in clause 5.1, the Board may admit New Participants where
there is insufficient Unallocated Pro Rata Entitlement (provided it has the consent of the Participants (save that no Participant shall unreasonably withhold, delay and/or condition their consent if Participants amounting to a Participant Majority
have provided their consent)) by such person signing a Deed of Adherence which shall set out such New Participant’s Pro Rata Entitlement. In such case the Pro Rata Entitlements of the existing Participants shall decrease by such amount pro
rata to their respective Pro Rata Entitlement so as to allocate the required Pro Rata Entitlement to the New Participant (unless the Participants (with the consent of the Board, which shall not be unreasonably withheld or
delayed) unanimously determine otherwise). 

  

	5.3	 A New Participant who has entered into a Deed of Adherence pursuant to this Deed
shall have the benefit of and be subject to the burden of all the provisions to this Deed as if he were a Participant, and this Deed shall be interpreted accordingly. Nothing in this clause shall be construed as requiring any New Participant
to perform again any obligation or discharge again any liability already performed or discharged or entitle any New Participant to receive again any benefit already enjoyed by the Participants prior to the New Participant becoming a party to this
Deed; and nothing herein shall be construed or interpreted to result in any Participant being obliged to make any compensation payments to the New Participant with respect to any Success Payment that has been paid to a Participant (including a
Disqualified Participant) or has become payable as a result of the achievement of a Milestone or the occurrence of an Exit prior to the date of the relevant Deed of Adherence. 

 

	6.	 TAX 

To the extent applicable, the Company shall be entitled to deduct: (a) any income tax due under PAYE and/or any employee national
insurance contributions or any equivalent tax in the relevant jurisdiction; and (b) any other deduction or withholding required by any law or regulation applicable to any Participant (and all and any other deductions required by law) with
respect to any Success Payment paid to such Participant pursuant to this Deed. 
  

	7.	 FURTHER ASSURANCE 

The parties shall at their own cost use all reasonable endeavours from time to time, on being required to do so by any other party, to do or
procure the doing of all such acts and/or execute 

  
 8 

 
or procure the execution of all such documents in a form reasonably satisfactory to the other party for giving full effect to this Deed and securing to the other parties the full benefit of the
rights, powers, privileges and remedies conferred upon any party in this Deed. 
  

	8.	 CONFIDENTIALITY 

 

	8.1	 The parties shall (and shall procure, where relevant, that each other member of its group and their respective
officers, employees, agents and advisers shall) preserve the confidentiality of the existence, the terms of this Deed and any information with respect to an Exit provided to the Participants in accordance clause 3.4, and, subject to clause 8.2, not
directly or indirectly reveal or disclose such information. 

  

	8.2	 Notwithstanding any other provision in this Deed, the parties may disclose the existence and the terms and
conditions of this Deed if and to the extent: 

  

	 	(a)	 required by applicable law or for the purpose of any judicial or arbitral proceedings; 

 

	 	(b)	 required by any securities exchange on which such party’s securities are listed or traded;

  

	 	(c)	 required by any regulatory or governmental or other authority with relevant powers to which such party is
subject or submits (whether or not the requirement has the force of law); 

  

	 	(d)	 required by its professional advisers (including auditors), officers, employees, consultants, sub-contractors or agents to provide their services (and subject always to similar duties of confidentiality) and any member of its group and their respective officers, employees, agents and advisers;

  

	 	(e)	 the Company has given its prior written consent to the disclosure; 

 

	 	(f)	 it is necessary to obtain any relevant tax clearances from or otherwise to disclose to comply with any
legislation, regulations, concessions, guidance or practice of any appropriate tax authority; or 

  

	 	(g)	 such information becomes publicly available (other than through a breach of this clause 8
(Confidentiality)). 

  

	9.	 COSTS AND EXPENSES 

The parties shall bear their own costs and disbursements incurred in the negotiations leading up to and in the preparation of this Deed and of
matters incidental to this Deed. 
  

	10.	 CUMULATIVE REMEDIES 

The rights, powers, privileges and remedies conferred upon the parties in this Deed are cumulative and are not exclusive of any other rights,
powers, privileges or remedies provided by law. 
  

	11.	 WAIVER 

The express or implied waiver by any party to this Deed of any of its rights or remedies arising under this Deed or by law shall not constitute
a continuing waiver of the right or remedy waived or a waiver of any other right or remedy. 
  

	12.	 ENTIRE AGREEMENT 

 

	12.1	 This Deed and the documents referred to or incorporated in it constitute the entire agreement between the
parties relating to the subject matter of this Deed and supersede and extinguish any prior drafts, agreements, undertakings, representations, warranties and arrangements of any nature whatsoever, whether or not in writing, between the parties in
relation to the subject matter of this Deed. 

  
 9 

	12.2	 Each of the parties acknowledges and agrees that it has not entered into this Deed in reliance on any statement
or representation of any person (whether a party to this Deed or not) other than as expressly incorporated in this Deed and the documents referred to or incorporated in this Deed. 

 

	12.3	 Without limiting the generality of the foregoing, each of the parties irrevocably and unconditionally waives
any right or remedy it may have to claim damages and/or to rescind this Deed by reason of any misrepresentation (other than a fraudulent misrepresentation) having been made to it by any person (whether party to this Deed or not) and upon which it
has relied in entering into this Deed (other than as expressly incorporated in this Deed and the documents referred to or incorporated in this Deed). 

  

	12.4	 Each of the parties acknowledges and agrees that damages alone may not be an adequate remedy for the breach of
any of the undertakings or obligations as set out in this Deed. Accordingly, without prejudice to any other rights and remedies the parties may have, the parties shall be entitled to seek the remedies of injunction, specific performance or other
equitable relief for any threatened or actual breach of the terms of this Deed. 

  

	12.5	 Nothing contained in this Deed or in any other document referred to or incorporated in it shall be read or
construed as excluding any liability or remedy as a result of fraud. 

  

	13.	 EFFECTIVENESS; TERMINATION 

 

	13.1	 The effectiveness of all rights and obligations under or in connection with this Deed shall be subject to the
condition precedent of the occurrence of Completion and all rights and obligations shall apply as from the date that such precedent is fulfilled; provided that if Completion has not occurred by the Longstop Date, this Deed shall
automatically terminate with immediate effect. 

  

	13.2	 Subject to clause 13.3, this Deed shall terminate and be of no further force or effect upon the earlier
of: 

  

	 	[####]	 

  

	 	[####]	 

  

	 	[####]	 

[####] 
  

	 	[####]	 

  

	 	[####]	 

  

	 	[####]	 

  
 10 

	13.3	 On termination of this Deed, clause 8 (Confidentiality) shall survive and continue in full force and
effect but all other rights and obligations of the parties shall cease immediately. Termination shall not affect the parties’ accrued rights and obligations as at such termination, in particular as set out in clauses 13.1 and 13.2 above.

  

	13.4	 For the avoidance of doubt, the occurrence of an Adverse Event shall not constitute grounds for any party to
terminate this Deed for cause or otherwise. 

  

	14.	 AMENDMENTS 

  

	14.1	 Subject to clauses 3.5 and 14.2, all and any of the provisions of this Deed may only be deleted, varied,
supplemented, restated or otherwise changed in any way at any time with the prior written consent of the Company, UM and Participants holding at least a majority of the aggregate Pro Rata Entitlements, in which event such change shall be binding
against all the parties hereto provided that if such change would impose any new obligations on any Participant(s) that is not imposed on all other Participants or increase any existing obligation of any Participant(s) that is not increased for all
other Participants, the consent of the affected Participant(s) to such amendment shall be specifically required. 

  

	14.2	 The Pro Rata Entitlements of the Participants may only be amended with the consent in writing of all of the
Participants (and the Board, which shall not be unreasonably withheld or delayed) or as otherwise provided for in accordance with clauses 3.5, 4 (Disqualified Participants) or 5.2. 

 

	15.	 SET OFF 

The Company may at any time set off any actual liability of any Participant to the Company (as applicable) against any actual liability of the
Company to the Participant, whether either liability is present or future, liquidated or unliquidated, and whether or not either liability arises under this Deed. If the liabilities to be set off are expressed in different currencies, the
Company may convert either liability at a market rate of exchange for the purpose of set-off. Any exercise by the Company of its rights under this clause shall not limit or affect any other rights or remedies
available to it under this Deed or otherwise. 
  

	16.	 NO PARTNERSHIP 

Nothing in this Deed is intended to or shall be construed as establishing or implying any partnership of any kind between the
parties. 
  

	17.	 ASSIGNMENT AND TRANSFER  

 

	17.1	 Subject to clauses 17.3 and 17.4, this Deed is personal to the parties and no party shall:

  

	 	(a)	 assign any of its rights under this Deed; 

 

	 	(b)	 transfer any of its obligations under this Deed; 

 

	 	(c)	 sub-contract or delegate any of its obligations under this Deed; or

  

	 	(d)	 charge or deal in any other manner with this Deed or any of its rights or obligations. 

 

	17.2	 Subject to clauses 17.3 and 17.4, any purported assignment, transfer,
sub-contracting, delegation, charging or dealing in contravention of clause 17.1 shall be ineffective. 

  

	17.3	 A Participant’s rights under this Deed shall be assigned automatically to their Personal Representative on
death and the Personal Representative shall notify UM of such assignment as soon as reasonably practical. 

  

	17.4	 A Participant or their Personal Representative can assign any rights under this Deed with consent in writing
from UM and on such terms and as determined by UM in its absolute discretion (save that in the case of a Personal Representative, UM’s consent shall not be unreasonably withheld, conditioned or delayed provided that the obligations and/or
liability of the Company and/or UM is not increased as a result of the assignment). 

  
 11 

	18.	 RIGHTS OF THIRD PARTIES 

This Deed does not confer any rights on any person or party (other than the parties) pursuant to the Contracts (Rights of Third Parties) Act
1999. 
  

	19.	 COUNTERPARTS; NO ORIGINALS 

This Deed may be executed in any number of counterparts, each of which shall constitute an original, and all the counterparts shall together
constitute one and the same agreement. The exchange of a fully executed version of this Deed (in counterparts or otherwise) by electronic transmission (including pdf or other digital format including any electronic signature complying with the
Electronic Signatures in Global and National Commerce Act 2000, e.g., www.docusign.com) and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes and shall be sufficient to
bind the parties to the terms and conditions of this Deed. No exchange of original signatures is necessary. 
  

	20.	 NOTICES 

  

	20.1	 To be valid, any communication and/or information to be given in connection with this Deed must be in writing
in English and either be delivered by hand or sent by first class post, email or other electronic form: 

  

	 	(a)	 to any body corporate which is a party at its registered office; or 

 

	 	(b)	 to any Participant at the address of that Participant shown in Schedule 1, 

or in each such case such other address as the recipient may notify to the other parties for such purpose in accordance
with this clause 20 (Notices). 
  

	20.2	 A communication sent according to clause 20.1 shall be deemed to have been received: 

(a) if delivered by hand, at the time of delivery; 

(b) if sent by pre-paid first class post, on the second day after posting; or 

(c) if sent by email or other electronic form, at the time of completion of transmission by the sender; 

except that if a communication is received between 17:30 on a Business Day and 09:30 on the next Business Day, it shall be deemed to have been
received at 09:30 on the second of such Business Days. 
  

	21.	 SEVERANCE 

  

	21.1	 If any provision of this Deed is held to be invalid or unenforceable by any judicial or other competent
authority, all other provisions of this Deed will remain in full force and effect and will not in any way be impaired. 

  

	21.2	 If any provision of this Deed is held to be invalid or unenforceable but would be valid or enforceable if some
part of the provision were deleted or modified, the provision in question will apply with the minimum modifications necessary to make it valid and enforceable. 

  
 12 

	22.	 GOVERNING LAW 

This Deed (and any dispute or claim relating to it or its subject matter (including non-contractual
claims)) is governed by and is to be construed in accordance with English law. 
  

	23.	 JURISDICTION 

The parties irrevocably agree that the courts of England and Wales shall have exclusive jurisdiction to settle any claim, dispute or issue
(including non-contractual claims) which may arise out of or in connection with this Deed. 

[Intentionally left blank, the schedules and signature pages follow.] 

  
 13 

 SCHEDULE 1 : [####] 

[####] 

  
 14 

 SCHEDULE 2 : [####] 

[####] 
 [####] 

[####] 
 [####] 

 

	[####]	 

  

	[####]	 

  

	[####]	 

[####] 
  

	[####]	 

  

	[####]	 

  

	[####]	 

  

	[####]	 

  

	[####]	 

  
 15 

 This Deed has been executed and delivered as a deed on the date shown on the first page. 

 

					
	Executed and delivered as a Deed by	  	)	  	
	 UNITED MEDICINES BIOPHARMA
	  	)	  	
	LIMITED	  	)	  	[####]
		  		  	[####]
	acting by: [####]	  		  	
	Position: [####]	  		  	
		  		  	
	 In the presence of:
	  		  	
		  		  	
	 Signature of Witness
	  		  	[####]
	 Name of Witness
	  		  	[####]
	 Address of Witness
	  		  	[####]
	 Occupation of Witness
	  		  	[####]
		  		  	
	Executed and delivered as a Deed by	  	)	  	
	MORPHOGEN-IX LIMITED	  	)	  	
		  	)	  	
                     
  

	acting by:	  		  	Signature
	Position:	  		  	
		  		  	
	In the presence of:	  		  	
		  		  	
	Signature of Witness	  		  	
                     
  

		  		  	
	Name of Witness	  		  	
                     
  

		  		  	
	Address of Witness	  		  	
                     
  

		  		  	
	Occupation of Witness	  		  	
                     
  

		  		  	
	Executed and delivered as a DEED by	  	)	  	
	[####]	  	)	  	
		  	)	  	
                     
  

		  		  	Signature
		  		  	
	In the presence of:	  		  	
		  		  	
	Signature of Witness	  		  	
                     
  

		  		  	
	Name of Witness	  		  	
                     
  

		  		  	
	Address of Witness	  		  	
                     
  

		  		  	
	Occupation of Witness	  		  	
                     
  

  
 16 

 This Deed has been executed and delivered as a deed on the date shown on the first page. 

 

					
	Executed and delivered as a Deed by	  	)	  	
	 UNITED MEDICINES BIOPHARMA
	  	)	  	
	LIMITED	  	)	  	
                     
  

		  		  	Signature
	acting by:	  		  	
	Position:	  		  	
		  		  	
	 In the presence of:
	  		  	
		  		  	
	 Signature of Witness
	  		  	
                     
  

		  		  	
	 Name of Witness
	  		  	
                     
  

		  		  	
	 Address of Witness
	  		  	
                     
  

		  		  	
	 Occupation of Witness
	  		  	
                     
  

		  		  	
	Executed and delivered as a Deed by	  	)	  	
	MORPHOGEN-IX LIMITED	  	)	  	
		  	)	  	[####]
	acting by: [####]	  		  	[####]
	Position: [####]	  		  	
		  		  	
	In the presence of:	  		  	
		  		  	
	Signature of Witness	  		  	 [####]

	Name of Witness	  		  	 [####]

	Address of Witness	  		  	 [####]

	Occupation of Witness	  		  	 [####]

		  		  	
	Executed and delivered as a DEED by	  	)	  	
	[####]	  	)	  	
		  	)	  	[####]
		  		  	[####]
		  		  	
	In the presence of:	  		  	
		  		  	
	Signature of Witness	  		  	 [####]

	Name of Witness	  		  	 [####]

	Address of Witness	  		  	 [####]

	Occupation of Witness	  		  	 [####]

  
 17 

					
	Executed and delivered as a DEED by	  	)	  	
	[####]	  	)	  	
		  	)	  	[####]
		  		  	[####]
		  		  	
	In the presence of:	  		  	
		  		  	
	Signature of Witness	  		  	[####]
	Name of Witness	  		  	[####]
	Address of Witness	  		  	[####]
	Occupation of Witness	  		  	[####]
		  		  	
		  		  	
		  		  	
		  		  	
	Executed and delivered as a DEED by	  	)	  	
	 [####]
	  	)	  	
		  	)	  	
                     
  

		  		  	Signature
		  		  	
	 In the presence of:
	  		  	
		  		  	
	 Signature of Witness
	  		  	
                     
  

		  		  	
	 Name of Witness
	  		  	
                     
  

		  		  	
	 Address of Witness
	  		  	
                     
  

		  		  	
	 Occupation of Witness
	  		  	
                     
  

		  		  	
		  		  	
		  		  	
		  		  	
	Executed and delivered as a DEED by	  	)	  	
	[####]	  	)	  	
		  	)	  	[####]
		  		  	[####]
		  		  	
	In the presence of:	  		  	
		  		  	
	Signature of Witness	  		  	[####]
	Name of Witness	  		  	[####]
	Address of Witness	  		  	[####]
	Occupation of Witness	  		  	[####]

  
 18 

					
	Executed and delivered as a DEED by	  	)	  	
	 [####]
	  	)	  	
		  	)	  	
                     
  

		  		  	Signature
		  		  	
	 In the presence of:
	  		  	
		  		  	
	 Signature of Witness
	  		  	
                     
  

		  		  	
	 Name of Witness
	  		  	
                     
  

		  		  	
	 Address of Witness
	  		  	
                     
  

		  		  	
	 Occupation of Witness
	  		  	
                     
  

		  		  	
		  		  	
		  		  	
		  		  	
	Executed and delivered as a DEED by	  	)	  	
	 [####]
	  	)	  	
		  	)	  	[####]
		  		  	[####]
		  		  	
	In the presence of:	  		  	
		  		  	
	Signature of Witness	  		  	[####]
	Name of Witness	  		  	[####]
	Address of Witness	  		  	[####]
	Occupation of Witness	  		  	[####]
		  		  	
		  		  	
		  		  	
		  		  	
	Executed and delivered as a DEED by	  	)	  	
	 [####]
	  	)	  	
		  	)	  	
                     
  

		  		  	Signature
		  		  	
	 In the presence of:
	  		  	
		  		  	
	 Signature of Witness
	  		  	
                     
  

		  		  	
	 Name of Witness
	  		  	
                     
  

		  		  	
	 Address of Witness
	  		  	
                     
  

		  		  	
	 Occupation of Witness
	  		  	
                     
  

  
 19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}]]